Literature DB >> 35818544

Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors: Triple Jeopardy?

Amy A Kirkham1, Coleen Power2, Edith Pituskin3.   

Abstract

Entities:  

Keywords:  body mass index; breast cancer; cardiotoxicity; echocardiography; heart failure; intermuscular fat; lifestyle risk factors; visceral fat

Year:  2022        PMID: 35818544      PMCID: PMC9270607          DOI: 10.1016/j.jaccao.2022.03.001

Source DB:  PubMed          Journal:  JACC CardioOncol        ISSN: 2666-0873


× No keyword cloud information.
Physical activity (PA) is universally recognized by the American Heart Association, the American College of Sports Medicine, and the European Society of Cardiology as an important strategy for primary prevention of cardiovascular disease (CVD). Within the field of cardio-oncology, positive experimental evidence in rodent models has generated enthusiasm for the role of structured exercise in the prevention of cardiotoxicity. Initial human studies have not demonstrated a significant effect of PA on cardiac function during anthracycline therapy. However, PA as a CVD risk reduction therapy is a lifestyle behavior, not just a brief intervention. In this issue of JACC: CardioOncology, Naaktgeboren et al report their evaluation of the relationship between PA and cardiac function among breast cancer survivors. Participants were well characterized, with anthracycline dose, radiation laterality, body mass index (BMI), and cardiovascular risk factors. Echocardiographic outcomes (global longitudinal strain [GLS] and left ventricular ejection fraction [LVEF]) were prespecified as impaired vs normal and performed and analyzed at 2 core laboratories. At a median of 10 years after treatment, higher levels of self-reported PA were associated with more favorable GLS but not LVEF. No patients had heart failure with reduced ejection fraction. Treatment-related and patient-related risk factors did not influence the results. With technical advances in echocardiography, GLS can be reliably assessed and is recognized as superior to LVEF for detecting subclinical changes. GLS reflects subendocardial fiber injury and detects subtle changes in wall motion despite normal LVEF. GLS and LVEF in cardio-oncology are typically evaluated in the active treatment setting. However, beyond treatment completion, LVEF is rarely systematically assessed. Declines to a threshold of <50% in the 10 to 12 years postdiagnosis have been noted to be less common, and Naaktgeboren et al similarly note rates of 3.65% to 7.2%. The investigators’ observation of impaired GLS a decade or more after definitive treatment is intriguing. To fully elucidate the contribution to physical dysfunction, GLS could be evaluated beyond the treatment phase to study the subclinical effects of risk reduction interventions. An expected effect of physical inactivity is a corresponding low cardiorespiratory fitness, or Vo2peak, an integrative measure of pulmonary, cardiovascular, and muscular systems. Physical inactivity and poor cardiopulmonary performance in breast cancer have been well documented, with survivors having Vo2peak equivalent to 20 to 30 years of premature aging. Bonsignore et al recently reported that next to age, GLS was the strongest univariable predictor of Vo2peak in 147 patients with HER2-positive early-stage breast cancer. Similar to the findings of Naaktgeboren et al, LVEF was not a predictor of Vo2peak. Deeper investigation of the mechanisms of impaired Vo2peak may provide insight into the reported 3-fold elevations in CVD risk in the breast cancer population. Moreover, among anthracycline-treated early-stage breast cancer survivors, we found that impaired cardiac reserve and thigh muscle fatty infiltration were associated with impaired oxygen extraction, both contributing to reduced Vo2peak. In a secondary analysis of the MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research) study, we observed a significant increase in fatty infiltration of skeletal muscle and increased visceral fat without concurrent change in BMI. BMI categories of overweight and obese are considered CVD risk factors, but BMI cannot distinguish body fat percentage or fat location. Although all of the Naaktgeboren et al models were adjusted for BMI, their least active group also had the greatest proportion of obesity. Moreover, BMI cannot distinguish body fat percentage or deposition. One in 4 obese cancer survivors are sarcopenic (low muscle mass), and this accumulation of fat has major health implications. Independent of CVD risk factors, elevated visceral and intermuscular fat are prognostic factors in both breast cancer–specific and overall survival., Accordingly, body composition represents a modifiable and therefore appealing target, particularly for PA interventions. However, promotion of PA remains a major challenge. Few breast cancer survivors achieve recommended PA levels, with participation in formal PA as low as 20%. It is notable that the Naaktgeboren et al study was set in the Netherlands, whose residents are known as among of the most physically active worldwide. This may account for the few inactive individuals (n = 28, or 5% of the total). These findings may not be generalizable to countries where inactivity is highly prevalent. Finally, it is worth reflecting that traditional exposures, namely anthracyclines and left-sided radiotherapy, did not influence the Naaktgeboren et al results. Two hundred fifty-three patients (45.3%) received nonanthracycline regimens, possibly combination therapies including cyclophosphamide, methotrexate, and fluorouracil. Radiation technologies have advanced significantly since the 2000s, now using computed tomographic planning, beam shaping, and breath-hold techniques to avoid organs at risk. It is possible that these traditional exposures have fewer long-term consequences in the modern treatment era. It is also possible that the predominance of physically active patients (95%) reduced the ability to detect these known cardiotoxic effects. Taken together, the Naaktgeboren et al paper represents a significant contribution to the study of long-term effects of cancer treatments, impact of habitual PA, and utility of sensitive imaging. This work will inform future study of holistic and individualized CVD risk reduction interventions such as pharmacotherapy, nutrition, and PA at effectual time points in the disease continuum.

Funding Support and Author Disclosures

Dr Pituskin is a Tier 2 Canada Research Chair. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
  17 in total

Review 1.  Nutrition and physical activity guidelines for cancer survivors.

Authors:  Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler
Journal:  CA Cancer J Clin       Date:  2012-04-26       Impact factor: 508.702

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  J Am Soc Echocardiogr       Date:  2014-09       Impact factor: 5.251

3.  Adjuvant CMF chemotherapy in operable breast cancer: ten years later.

Authors:  G Bonadonna; A Rossi; P Valagussa
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

4.  Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

Authors:  Lee W Jones; Kerry S Courneya; John R Mackey; Hyman B Muss; Edith N Pituskin; Jessica M Scott; Whitney E Hornsby; April D Coan; James E Herndon; Pamela S Douglas; Mark Haykowsky
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

Review 5.  Clinical Implications of Sarcopenic Obesity in Cancer.

Authors:  Isabella P Carneiro; Vera C Mazurak; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

6.  Echocardiographic global longitudinal strain is associated with infarct size assessed by cardiac magnetic resonance in acute myocardial infarction.

Authors:  Gowsini Joseph; Tomas Zaremba; Martin Berg Johansen; Sarah Ekeloef; Einar Heiberg; Henrik Engblom; Svend Eggert Jensen; Peter Sogaard
Journal:  Echo Res Pract       Date:  2019-08-07

7.  Increased Risk of Cardiovascular Death in Breast Cancer Patients Without Chemotherapy or (and) Radiotherapy: A Large Population-Based Study.

Authors:  Tianwang Guan; Hanbin Zhang; Jinming Yang; Wenrui Lin; Kenie Wang; Miao Su; Weien Peng; Yemin Li; Yanxian Lai; Cheng Liu
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 6.244

8.  Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy.

Authors:  Alis Bonsignore; Thomas H Marwick; Scott C Adams; Babitha Thampinathan; Emily Somerset; Eitan Amir; Mike Walker; Husam Abdel-Qadir; C Anne Koch; Heather J Ross; Anna Woo; Bernd J Wintersperger; Mark J Haykowsky; Paaladinesh Thavendiranathan
Journal:  JACC CardioOncol       Date:  2021-11-16

9.  The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review.

Authors:  James Murray; Hunter Bennett; Eva Bezak; Rebecca Perry
Journal:  Eur J Prev Cardiol       Date:  2022-03-25       Impact factor: 7.804

10.  Cardiac and skeletal muscle predictors of impaired cardiorespiratory fitness post-anthracycline chemotherapy for breast cancer.

Authors:  Amy A Kirkham; Mark J Haykowsky; Rhys I Beaudry; Justin G Grenier; John R Mackey; Edith Pituskin; D Ian Paterson; Richard B Thompson
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.